From the CEO

Once again, watch Stan Erck interviewed on CNBC's Mad Money with Jim Cramer 02/13/15

Watch Stan Erck interviewed on CNBC's Mad Money with Jim Cramer 01/15/15

Watch BioWorld interview with Stan Erck 10/31/14

Listen to BioTech Nation Radio Interview with Stan Erck 10/29/14

Watch coverage of Novavax Ebola Program from ABC News Channel 7 WJLA 10/28/2014

Watch Stan Erck's Interview on CNBC discussing the new Ebola Program 10/27/2014

Watch Stan Erck's Interview on The Street 09/23/2014

At Novavax, we’ve brought together state-of-the-art science, cutting-edge manufacturing techniques, and passionate, talented professionals to create the vaccines of tomorrow. In light of today’s critical health concerns, we aim to provide real solutions through rapid vaccine production worldwide. We believe that halting the spread of contagious diseases is possible through innovation and perseverance.

— Stanley C. Erck, President & CEO

About Novavax

Novavax, Inc. (Nasdaq: NVAX) is a clinical-stage biopharmaceutical company creating novel vaccines and vaccine adjuvants to address a broad range of infectious diseases worldwide. Using innovative proprietary recombinant protein nanoparticle vaccine technology, the company produces vaccine candidates to efficiently and effectively respond to both known and newly emergent diseases. Novavax is involved in several international partnerships, including collaborations with Cadila Pharmaceuticals of India, LG Life Sciences of Korea, PATH and recently acquired Isconova AB, a leading vaccine adjuvant company located in Sweden. Together, Novavax' network supports its global commercialization strategy to create real and lasting change in the biopharmaceutical and vaccinology fields. Additional information about Novavax is available on the company's website,